HAS A 3-FOLD DECREASED DOSE OF BACILLUS CALMETTE-GUERIN THE SAME EFFICACY AGAINST RECURRENCES AND PROGRESSION OF T1G3 AND TIS BLADDER TUMORS THAN THE STANDARD DOSE? RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL-Reference-Cited by-同舟云学术

HAS A 3-FOLD DECREASED DOSE OF BACILLUS CALMETTE-GUERIN THE SAME EFFICACY AGAINST RECURRENCES AND PROGRESSION OF T1G3 AND TIS BLADDER TUMORS THAN THE STANDARD DOSE? RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL

Published:2005-10 Issue:4 Part 1 Volume:174 Page:1242-1247
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

MARTÍNEZ-PIÑEIRO JOSÉ A.¹,MARTÍNEZ-PIÑEIRO LUIS¹,SOLSONA EDUARDO¹,RODRÍGUEZ RAFAEL HERNÁNDEZ¹,FERNÁNDEZ GÓMEZ JESÚS MARÍA¹,MARTÍN MARCELINO GONZÁLEZ¹,MOLINA JESÚS RODRÍGUEZ¹,COLLADO ANABEL GIMENO¹,FLORES NICOLÁS¹,ISORNA SANTIAGO¹,PERTUSA CARLOS¹,RABADÁN MARIANO¹,ASTOBIETA ANDER¹,CAMACHO JOSÉ EMILIO¹,ARRIBAS SALVADOR¹,MADERO ROSARIO¹,

Affiliation:

1. From the La Luz Clinic (JAM-P), La Paz Hospital (LM-P, SA, RM) and Hospital de San Carlos (JRM), Madrid, Instituto Valenciano de Oncología (ES), Valencia, Valdecilla Hospital (RHR), Santander, Complejo Hospitalario de Oviedo (JMFG) and Hospital Juan Canalejo (MGM), La Coruña, Hospital La Mancha (AGC), Alcázar de San Juan, Hospital Civil de Basurto (NF) and Hospital de Cruces (CP), Bilbao, Hospital Negrín (SI), Las Palmas, Hospital de la Princesa (MR) and Hospital de Galdácano (AA), Vizcaya and...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference20 articles.

1. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer;Martínez-Pineiro;BJU Int,2002

2. Low dose vs standard dose BCG therapy of superficial bladder cancer: final results of a phase 3 randomized trial;Bassi;Eur Urol, suppl.,1999

3. Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer;Morales;J Urol,1992

4. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder;Mack;J Urol,2001

5. Low-dose bacille Calmette-Guerin (BCG) therapy in superficial high-risk bladder cancer: a phase II study with the BCG strain Connaught Canada;Mack;Br J Urol,1995

Cited by 169 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Experience of organizing BCG therapy for localized bladder cancer in outpatient cancer care centers;Consilium Medicum;2024-08-30

2. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update;European Urology;2024-08

3. Carcinoma In Situ (CIS): Is There a Difference in Efficacy between Various BCG Strains? A Comprehensive Review of the Literature;Cancers;2024-01-05

4. Novel immunotherapeutic options for BCG‐unresponsive high‐risk non‐muscle‐invasive bladder cancer;Cancer Medicine;2023-12

5. The Impact of Dose Reduction of Bacillus Calmette–Guerin on Oncological Outcomes and Toxicity in Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis;Bladder Cancer;2023-09-25